Eli Lilly Pays $2.4 Billion for Orna Therapeutics to Push Forward Next-Generation Cell Therapy

Eli Lilly acquires Orna Therapeutics for up to $2.4B, advancing in vivo CAR-T cell therapy using circular RNA and stem cells research to treat autoimmune diseases.

Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Next-Generation Cell Therapy

What if your body could be instructed to heal itself — without the need for weeks of laboratory procedures or hospital stays? That is the central idea behind Eli Lilly’s decision to acquire Orna Therapeutics for up to $2.4 billion, announced on February 9, 2026. The deal centers on a technology that uses engineered RNA molecules to reprogram the body’s own immune cells from within, representing a significant step forward in the evolving field of cell therapy and stem cells research.

What Is the Deal and Why Does It Matter?

Eli Lilly, one of the world’s largest pharmaceutical companies, has agreed to pay up to $2.4 billion in cash to acquire Orna Therapeutics, a biotechnology company specializing in circular RNA technology. The payment includes an upfront sum plus additional payments tied to how well the company’s lead treatment performs in clinical trials.

The acquisition gives Eli Lilly full ownership of Orna’s core technology platform, its delivery system, and its most advanced drug candidate — a therapy called ORN-252. This is not just a single-product purchase. Eli Lilly is buying an entire technology infrastructure that it believes can be applied to multiple diseases beyond its initial target.

This move fits a pattern the company has been building. Eli Lilly has used revenue generated from its highly successful weight management drugs — including tirzepatide, sold under the brand names Mounjaro and Zepbound — to invest in emerging areas of medicine, including gene editing and now RNA-based cell therapy.

Who Is Orna Therapeutics and What Did They Build?

Orna Therapeutics is a biotechnology company that developed a new type of RNA molecule called circular RNA, or oRNA. To understand why this matters, it helps to know a little about how traditional RNA therapies work.

Most RNA-based drugs, such as the mRNA vaccines developed during the COVID-19 pandemic, are built from linear RNA — a molecule with two open ends that breaks down relatively quickly inside the body. Orna’s circular RNA, by contrast, forms a closed loop with no open ends, making it significantly more stable. It lasts longer inside cells, produces proteins for a longer period, and is easier to manufacture consistently.

Orna pairs this circular RNA with a delivery vehicle called a lipid nanoparticle, or LNP — essentially a tiny fat-based capsule that carries the RNA into specific cells in the body. Together, the circular RNA and LNP form the foundation of a platform that can potentially be used across many disease areas, including autoimmune conditions, cancer, and genetic disorders.

The Lead Drug Candidate: ORN-252

Orna’s most advanced program is ORN-252, an experimental in vivo CAR-T therapy targeting a protein called CD19, which is found on the surface of B cells — a type of immune cell. ORN-252 has completed preclinical testing and was described at the time of the acquisition announcement as ready to enter clinical trials in human patients.

What Makes ORN-252 Different from Traditional CAR-T Therapy?

To appreciate what ORN-252 offers, it is helpful to understand how standard CAR-T therapies currently work. In the traditional process, doctors extract T cells from a patient’s blood, send them to a specialized laboratory where they are genetically modified over a period of several weeks, and then reinfuse the modified cells back into the patient. This process is time-consuming, technically complex, and extremely expensive — often running into hundreds of thousands of dollars per patient.

ORN-252 takes a fundamentally different approach. Rather than removing cells from the body and modifying them externally, the therapy is injected directly into the patient. The circular RNA payload — delivered via LNPs — travels to the patient’s own T cells and reprograms them inside the body to become CAR-T cells. This approach, known as in vivo cell reprogramming, has the potential to be administered in an outpatient setting, without the lengthy manufacturing process associated with traditional cell therapies.

Which Diseases Could It Treat?

ORN-252 is being developed to treat B-cell-driven autoimmune diseases — conditions where the immune system mistakenly attacks the body’s own tissues. Examples include systemic lupus erythematosus (SLE) and rheumatoid arthritis, both of which involve abnormal B-cell activity. By using CAR-T cells to selectively eliminate these problematic B cells, ORN-252 aims to interrupt the disease process at its source. Some researchers have described this mechanism as offering a potential long-term immune system reset, though this remains to be confirmed through clinical trials.

Why Is Eli Lilly Making This Move Now?

The Autoimmune Disease Market

Autoimmune diseases affect hundreds of millions of people worldwide and represent one of the largest areas of unmet medical need in modern medicine. Current treatments — including monoclonal antibodies and immunosuppressive drugs — can help manage symptoms and slow disease progression, but they rarely address the underlying immune dysfunction in a lasting way. Patients often require lifelong treatment and may experience diminishing responses over time.

In vivo cell therapies like ORN-252 offer a mechanistically different option, one with the potential for more durable outcomes. This has made the autoimmune space increasingly attractive to major pharmaceutical companies looking for the next generation of treatments to follow conventional biologics.

A Platform, Not Just a Product

Eli Lilly is not simply acquiring one drug. The oRNA-LNP-in vivo reprogramming platform that underpins ORN-252 is designed to be broadly applicable. In theory, the same technological foundation could be adapted to develop treatments in oncology, rare genetic diseases, and other areas where targeted cellular reprogramming could be beneficial — including applications adjacent to stem cells research, where RNA tools are increasingly being used to influence cell behavior and differentiation.

By acquiring Orna at this stage — after preclinical validation but before large-scale clinical trials — Eli Lilly gains access to a mature platform while avoiding the highest-risk phase of early-stage scientific discovery.

How Does This Fit Into the Broader Industry Picture?

Eli Lilly is not the only major pharmaceutical company moving in this direction. Over the past several years, a number of large organizations have made significant investments in in vivo CAR-T technology:

Gilead Sciences acquired Interius BioTherapeutics for around $350 million. AbbVie purchased Capstan Therapeutics for up to $2.1 billion. Bristol Myers Squibb invested $1.5 billion in Orbital Therapeutics.

Taken together, these transactions indicate that in vivo cell therapy has moved from a niche research concept to a mainstream strategic priority for the global pharmaceutical industry. Eli Lilly’s acquisition of Orna confirms its entry into this competitive space and reflects a wider industry belief that this technology could become a defining feature of next-generation medicine.

Internationally, research activity in this area is also expanding. Around nineteen companies in China are reported to be developing in vivo CAR-T programs, using both viral vector and LNP-based delivery methods. Some of these programs have begun early-stage clinical testing. One company, Hongxin Bio, reported a 60% T-cell reprogramming rate and notable B-cell clearance in a preclinical lupus model — results that, while preliminary, highlight the global scale of interest in this approach.

What Comes Next?

The year 2026 is expected to be an important one for the in vivo CAR-T field, with several programs — including ORN-252 — anticipated to generate early clinical data from first-in-human studies. These results will be critical in determining whether the promising signals seen in preclinical research translate into meaningful, measurable benefit for patients.

Regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency will play an important role in shaping how these therapies are evaluated and approved. As the evidentiary standards for this new class of treatments continue to develop, the clinical data emerging from 2026 onward will help define both the promise and the limitations of in vivo cell reprogramming as a therapeutic strategy.

Eli Lilly’s acquisition of Orna Therapeutics is, at its core, a long-term investment in a technology that could change how cell-based therapies are manufactured and delivered. Rather than treating each patient through a slow, costly, individualized process, the vision is one where a standardized, injectable product programs the body’s own cells to do the work — making advanced cell therapy potentially faster, cheaper, and more widely accessible.